Research

Current Studies

The Children’s Kidney Center is one of only a few in the country to participate in clinical drug trials that are improving the odds for children with renal disease, including multiple multicentric studies in the fields of hypertension, Hemolytic Uremic Syndrome (HUS) and FocalSegmental Glomerulo sclerosis (FSGS). The results of these studies and the experience of this program have been presented internationally at professional meetings and published in medical journals.

Current research includes the study of:

  • medications for the correction of anemia in pediatric patients with chronic renal failure.
  • new medication to optimize growth while being treated for chronic renal failure.
  • Patient education campaign, “Eat Healthy to Live Longer”, to assess the impact of “extra measures” -- pedometers, discounted gym memberships and DVDs -- in the nutritional outcome of children with essential hypertension.

Abstracts

ES Woodle…..I. Roberti….A prospective, multicenter collaborative experience with a proteasome inhibitor based protocol for antibody mediated rejection (AMR): results in early versus late AMR. ATC 2011

ES Woodle…..I. Roberti….A multicenter, prospective, collaborative evaluation of proteasome inhibition for the treatment of antibody mediated rejection in solid organ transplantation. ATC 2011

ES Woodle…..I. Roberti….Factors that influence donor specific antibody response to proteasome inhibitor for antibody mediated renal allograft rejection: multivariate analysis from a multicenter collaborative effort. ATC 2011

Vyas S, Roberti I. Highly successful therapy of early FSGS recurrence post kidney transplant: a single center experience. IPTA meeting, 2011, Vancouver

Roberti I, Jean M, Vyas S. Long-term follow-up of children with essential hypertension – are we minimizing end-organ injury? ASN meeting 2011, PA

Saint Barnabas Medical Center Research Day, April 2011, Dr. Vyas and Dr. Roberti presented 2 posters

Roberti, I et al. Successful rescue of refractory acute antibody-mediated renal allograft rejection with splenectomy - a case report. Ped Transpl, 2012; 16 (2):E49-52

Vyas, S, Roberti, I - Are we achieving are goals of minimizing end organ damage in children with essential hypertension? J. Hypertension, in press

Roberti I, Vyas, S. Successful treatment of severe a AMR of renal allografts with bortezomib: 2 cases report. Ped Transplant, 2015, in print

Rachel Gwertzman, Howard Corey, Ryanne Pastini, Isabel Roberti.Autoimmune polyglandular syndrome Type I complicated by tubulo-interstitial nephritis - report of 2 cases. Ped Nephrol, 2015, in print

Publications

Successful rescue of refractory acute antibody-mediated renal allograft rejection with splenectomy--a case report. Roberti I. Geffner S. Vyas S. Pediatric Transplantation. 16(2):E49-52, 2012 Mar. [Journal Article]
Read now

Lymphocyte ATP immune cell function assay in pediatric renal transplants: is it useful? Vyas S. Roberti I. Transplantation Proceedings. 43(10):3675-8, 2011 Dec. [Evaluation Studies. Journal Article]
Read now

Long-term outcome of children with steroid-resistant nephrotic syndrome treated with tacrolimus. Roberti I. Vyas S. Pediatric Nephrology. 25(6):1117-24, 2010 Jun. [Journal Article]
Read now

A single-center study of C1q nephropathy in children. Roberti I. Baqi N. Vyas S. Kim DU. Pediatric Nephrology. 24(1):77-82, 2009 Jan. [Journal Article]
Read now

May-Thurner syndrome in a pediatric renal transplant recipient--case report and literature review. Vyas S. Roberti I. McCarthy C. Pediatric Transplantation. 12(6):708-10, 2008 Sep. [Case Reports. Journal Article]
Read now

Research

Protocol #01-68 (added) (PI) FSGS registry – Council of Pediatric Nephrology and Urology NKF NY/NJ - 1999-present.

Protocol #2008 - A multicentric, double-blind randomized study evaluating de novo weekly and once every 2 weeks darbepoetin alfa dosing for the correction of anemia of pediatric subjects with CKD receiving or not receiving dialysis.

Protocol #10- 17- A retrospective observational study to describe changes in biochemical markers and occurrence of safety events following treatment with cinacalcet HCL in pediatric subjects with CKD and secondary Hyperparathyroidism receiving dialysis.

Protocol # 2014 - Cinacalcet in children with secondary hyperparathyroidism on dialysis.

[ top ]